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Thyroid carcinoma is generally associated with good prognosis, but no effective treatments are currently
available for aggressive forms not cured by standard therapy. To ﬁnd novel therapeutic targets for this
tumor type, we had previously performed a siRNA-based functional screening to identify genes essential
for sustaining the oncogenic phenotype of thyroid tumor cells, but not required to the same extent for
the viability of normal cells (non-oncogene addiction paradigm). Among those, we found the coatomer
protein complex z1 (COPZ1) gene, which is involved in intracellular trafﬁc, autophagy and lipid ho-
meostasis. In this paper, we investigated the mechanisms through which COPZ1 depletion leads to
thyroid tumor cell death. We showed that siRNA-mediated COPZ1 depletion causes abortive autophagy,
endoplasmic reticulum stress, unfolded protein response and apoptosis. Interestingly, we observed that
mouse tumor xenografts, locally treated with siRNA targeting COPZ1, showed a signiﬁcant reduction of
tumor growth. On the whole, we demonstrated for the ﬁrst time the crucial role of COPZ1 in the viability
of thyroid tumor cells, suggesting that it may be considered an attractive target for novel therapeutic
approaches for thyroid cancer.
© 2017 Elsevier B.V. All rights reserved.Introduction
Cancer cells often depend on non mutated genes and pathways
to support their unchecked growth. The activity of these genes is
essential for tumor cells, but not required to the same extent by
normal cells; this concept is known as “non-oncogene addiction”
(NOA) paradigm [1]. NOA genes represent tumor vulnerabilities
and their inhibition results in the failure of the oncogenicsul Cancro (AIRC) [Grant IG
ndazione Umberto Veronesi
azionale dei Tumori, Via G.A.
(A. Greco).phenotype. Nowadays, large-scale siRNA-based functional
screening of cancer cell lines represent a powerful strategy for the
identiﬁcation of NOA genes that can be investigated as therapeutic
targets for many types of tumors [2]. We used this approach to
unveil nodal points for therapeutic intervention for thyroid carci-
noma (TC), which represents the most frequent endocrine cancer,
with a rapidly increasing incidence [3].
The majority of TC originates from epithelial cells and includes
well-differentiated papillary (PTC) and follicular (FTC) carcinomas,
poorly differentiated (PDTC) and undifferentiated anaplastic car-
cinomas (ATC). Most TCs are effectively treated by standard ther-
apy, involving surgery, thyroid stimulating hormone and
radioiodine. Nevertheless, a fraction of patients cannot be cured
due to local recurrence (in up to 20% of patients), distant metastasis
(in approximately 10% at 10 years [4]) and/or radioresistant disease.
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nosis, with survival of few months in the case of ATC [5,6]. Even
though recent molecular ﬁndings allowed the development of
several therapies designed to speciﬁcally target thyroid oncopro-
teins or their downstream pathways, this strategy showed modest
results and only partial response [7,8]. Few or no therapeutic op-
tions are currently available for patients with aggressive and
iodine-refractory thyroid tumors. Thus, there is a need to better
understand the mechanisms of thyroid carcinogenesis and to
improve the treatment of the most aggressive tumor forms not
curable by standard therapy.
We have recently discovered several thyroid tumor cell vul-
nerabilities. By screening a siRNA library, we identiﬁed a set of
genes whose silencing inhibited the growth of a panel of thyroid
tumor cells, but not of normal immortalized thyrocytes. The COPZ1
gene was found among the top ranked genes [9]. COPZ1 (coatomer
protein complex z1) belongs to the coatomer protein complex I
(COPI), an heptameric complex which is involved in: assembly of
coated vesicles on Golgi membranes, retrograde transport of
luminal andmembrane proteins in the ER-Golgi secretory pathway,
endosome maturation, autophagy [10,11] and lipid homeostasis
[12]. It has been demonstrated that COPZ1 knockdown causes cell
death in both proliferating and nondividing tumor cells. Unlike
tumor cells, normal cells are not sensitive to COPZ1 inhibition [13].
We identiﬁed COPZ1 as a thyroid tumor cell speciﬁc survival gene,
as its inhibition induced cell death in tumor cell lines but not in
immortalized thyrocytes. This evidence, together with a not sig-
niﬁcant variation of expression and absence of mutations in PTC,
allowed us to classify COPZ1 as an example of “non-oncogene
addiction” for thyroid cancer cells [9].
Here we investigated the mechanisms through which COPZ1
depletion leads to thyroid tumor cell death and explored its po-
tential use as therapeutic target for thyroid carcinoma. We found
that cell death induced by COPZ1 depletion is associated with
abortive autophagy, ER stress, UPR and apoptosis. Interestingly,
local treatment with siCOPZ1 oligos reduced tumor growth in an
in vivo model of thyroid carcinogenesis.
Materials and methods
Cell lines
Thyroid tumor cell lines, primary thyrocytes and mammary epithelial h-TERT-
HME1 cells were cultured as previously described [9,14,15]. Source and culture
conditions are reported in Supplementary. GFP-LC3 stable cell lines were generated
by transfecting 2 mg of pEGFP-LC3 plasmid (from Tamotsu Yoshimori's laboratory
[16], using the Lipofectamine 3000 reagent (Invitrogen Life Technologies, Carlsbad,
CA, USA) for TPC-1, and Lipofectamine LTX (Invitrogen Life Technologies) for 8505C
cells, according to manufacturer's instruction. Transfected cells were selected and
propagated in medium containing G418 (500 mg/ml, Invitrogen Life Technologies).
Detection of LC3 puncta
Cells growing on glass coverslips were transfected as described below and 24 h,
48 h, 72 h later ﬁxed for 20 minwith 4% paraformaldehyde. After washing with PBS,
cells were treated with the ProLong Diamond Antifade mountant with DAPI
(P36966, Molecular Probes, Invitrogen Life Technologies) and imaged with immu-
noﬂuorescence microscopy (Eclipse E1000; Nikon Instruments, Inc. NY, USA). The
percentage was calculated as the ratio between cells displaying LC3 puncta and total
cells (at least 150), considering six randomly selected 60 ﬁelds.
siRNA reagents and transfection
siRNA transfection was performed using 20 nM of siRNA oligos (see list in
Supplementary) and the Lipofectamine RNAiMAX reagent (Invitrogen Life Tech-
nologies), according to manufacturer's instruction.
Colony formation assay
Cells were plated in 100 mm dishes and transfected the following day with
20 nM of siRNAs. One day later, cells were collected and plated as follows:
2  104 cells in 24 well-plates for colony formation assay; 1.5  105 cells in 60 mm
dishes for western blot analysis. For the colony formation assay, cells were ﬁxed ﬁvedays later with formaldehyde 3.7% v/v solution for 30 min, washed with PBS and
stained for 20 minwith 0.1% crystal violet (w/v). Pictures were taken using an Epson
image scanner.
Western blot analysis
WB analysis was performed as previously described [17]. The list of antibodies is
provided in Supplementary.
RNA extraction and real time PCR
RNA extraction and Real time PCR were performed as previously described [17].
The following TaqMan gene expression assays (Applied Biosystem, Foster City, CA)
were used: Hs01023197_m1 for COPZ1 and Hs00358796_g1 for CHOP expression;
Hs02800695_m1 for HPRT1, used as housekeeping gene for normalization among
samples.
Apoptosis assay
Cells were transfected with 20 nM of siRNA oligos in the presence of 2 mM of the
ﬂuorogenic substrate for activated caspase-3/7 (CellEvent™ Caspase-3/7 Green
Detection Reagent, Invitrogen Life Technologies). Live-cell ﬂuorescence images were
taken 72 h later with microscope (Eclipse TE2000-S; Nikon Instruments).
In vivo studies
Female CD-1 nu/numice (5-weeks old) (Charles River, Calco, Italy) were injected
subcutaneously into the left ﬂank with 8505C cells (10  106). When xenograft
tumors reached the mean volume of 0.085 mm3 (range 0.040e0.144), they were
randomly divided into three groups and then locally treated with 20 mg of siCOPZ1
oligos (4457308, Ambion® ID s22427) or non-targeting oligos (4457289, Ambion®
In Vivo Negative Control #1 siRNA) mixed in 50 ml of MaxSuppressor™ In Vivo RNA-
LANCEr II reagent (Bioo Scientiﬁc, Austin, TX, USA), or with MaxSuppressor™ only.
Treatments were carried out at day 17, 20, 23, 27, 30 after cell injections. Tumor
growth was followed for 34 days and assessed bymonitoring tumor weight (TW), as
previously described [18]. Animal studies were reviewed and approved by the Ethics
Committee for Animal Experimentation of the hosting institution and are in
accordance with the guidelines of the UK Coordinating Committee for Cancer
Research [19].
Immunohistochemistry
Serial sections from parafﬁn-embedded tumor xenografts (2-mm thick) were
stained with hematoxylin and eosin and evaluated under a light microscope to
assess the pattern of tumor growth. Antigen retrieval was performed using 1 mM
citrate buffer (pH 6), then sections were immunostained with a primary rat poly-
clonal antibody anti-human COPZ1 (1:400 SAB4500896 Sigma-Aldrich St Louis, Mo,
USA), anti-human Ki-67 (Mib1) (1:200 M7240 Dako, Agilent Technologies, CA, USA).
Immunostains were performed using standard immunoperoxidase protocol fol-
lowed by diaminobenzidine chromogen reaction (Dako REAL™ EnVision™ Detec-
tion System, K5007 Dako). The intensity of staining for COPZ1 was scored as low
(1þ), medium (2þ) or high (3þ). The percentage of cells immunostained for Ki67
and necrotic cells was estimated counting one 10 ﬁeld, randomly selected. One
sample of each group of tumor explants was excluded from the IHC analysis due to
technical problems.
Gene/miRNA expression analysis
Gene expression data of COPZ2 gene (log scale) from 58 normal-thyroid tissue
samples compared to 31 ATC, 72 PTC and 17 PDTC samples, were obtained
combining GSE3467 [20], GSE6004 [21], GSE33630 [22,23] and GSE76039 [24]
publicly available datasets. Raw intensity expression values on U133 Plus 2.0 array
(Affymetrix, Santa Clara, CA) were processed by Robust Multi-array Average pro-
cedure [25], with the re-annotated Chip Definition Files from BrainArray libraries
version 20.0.0 [26], available at http://brainarray.mbni.med.umich.edu. Batch effects
were removed by using sva R/Bioconductor package [27]. The analysis of the thyroid
TCGA dataset from 58 paired normal/PTC samples was performed as previously
described [9]. Normalized reads per million miRNA mapped (RPM) data were ob-
tained for the same 58 tumor samples from Illumina HiSeq Level 3 isoform quan-
tiﬁcation ﬁles (TCGA Data Portal website), by summing up the reads aligned to each
3p or 5p miRBase v16 mature strands [28,29]. Pearson's correlation method was
applied to evaluate the correlation between RNAseq normalized gene and miRNA
read counts (log scale) in 58 tumor samples.
Results
COPZ1 depletion affects thyroid tumor cell viability
The issue that COPZ1 represents vulnerability for thyroid tumor
cell lines but not for normal thyrocytes [9] is further documented
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oligos targeting COPZ1 (siCOPZ1), a drastic growth inhibition was
observed in thyroid tumor cell lines (PTC-derived: BCPAP and TPC-
1; FTC-derived: WRO82-1; ATC-derived: 8505C, KAT-18, and HTC/
C3) in comparison to non-targeting (siNT) transfected cells, and to
COPZ1-depleted Nthy-ori 3-1 cells, normal immortalized thyro-
cytes. Western blot (WB) analysis performed in parallel docu-
mented the efﬁcient COPZ1 silencing in all the cell lines (bottomFig. 1. Effect of COPZ1 silencing on cell viability. (A) Colony forming assay of thyroid cell line
Nthy-ori 3-1, TPC-1, 8505C, HTC/C3 cells, primary normal thyrocytes and human mammary e
(C), cells were assessed by WB for protein levels of COPZ1 72 h after siRNA transfection; b-
siRNAs targeting COPZ1; siUBB: siRNA targeting Ubiquitin B.panel). SiRNA transfected TPC-1, 8505C, HTC/C3, and Nthy-ori 3-
1 cell lines were also analyzed by time-lapse phase-contrast video
microscopy (Supplementary Videos). Unlike siNT-transfected cells,
COPZ1-depleted tumor cells showed morphological changes, such
as shrinking and rounding up 30 h (for TPC-1 cells) and 48 h (for
8505C and HTC/C3 cells) after silencing Then, cells detached from
dishes and reached massive cell death at the end of the experiment
(68 h for TPC-1 cells, 89 h for 8505C and HTC/C3 cells). None ofs, 5 days after siRNA transfection; (B-C) Representative pictures at 10magniﬁcation of
pithelial cells (HME-1) at the indicated time points after siRNA transfection. In (A) and
actin was used for normalization of gel loading. siNT: Non-Targeting siRNAs; siCOPZ1:
M.C. Anania et al. / Cancer Letters 410 (2017) 201e211204these effects was observed in COPZ1-depleted NThy-ori 3-1 cells,
which proliferated as the control (siNT) and reached conﬂuence at
the end of the experiment (68 h). In Fig. 1B, representative images
of each cell lines at the end of experiment are reported. Further
images documenting cell morphological changes after COPZ1
depletion are shown in Supplementary Fig. S1. We also showed the
lack of effect of COPZ1 silencing on primary human thyrocytes and
human mammary epithelial HME-1 (Fig. 1C): COPZ1 depletion
leaves unaffected the growth of these nonmalignant cells, similarly
to the negative control siNT; on the contrary, a massive cell death
was observed in cells transfected with siRNA oligos targeting
Ubiquitin B (siUBB), used as control. WB analysis 72 h after siRNA
transfection documented the complete abrogation of COPZ1 pro-
tein expression.
Supplementary data related to this article can be found online at
https://doi.org/10.1016/j.canlet.2017.09.024
COPZ1 depletion affects autophagy
COPI complex members are involved in autophagy [11] and are
required for completion of the autophagic process. Moreover, the
depletion of COPI members impairs productive autophagy, as
demonstrated in prostate, breast and ovarian carcinoma cells
[13,30]. TPC-1 and 8505C cell lines, stably expressing the auto-
phagosome marker GFP-LC3 (hereafter referred as TPC1-GL3 and
8505-GL3) were transfected with siCOPZ1 and siNT oligos and
analyzed at different time points by ﬂuorescence microscopy for
the presence of the typical autophagy-associated LC3 puncta
(Fig. 2A). The number of siNT-transfected cells displaying LC3
puncta remained low over the time. On the contrary, the number of
COPZ1-depleted cells presenting puncta signiﬁcantly increased
over the time. In TPC1-GL3 cells puncta were detected in 5.7% and
38% at 24 h and 48 h, respectively; the analysis at 72 h was not
feasible, as cells detached from glass coverslip due to the lethal
effect of COPZ1 silencing. In 8505-GL3 cells, puncta were present in
6%, 14% and 34%, at 24 h, 48 h and 72 h, respectively. In Fig. 2B,
representative images of COPZ1-depleted cells displaying LC3
puncta and relative controls are shown. Autophagosome formation
upon COPZ1 silencing was also demonstrated by assessing the
conversion of the endogenous LC3-I to LC3-II by WB. Accumulation
of LC3-II protein was observed in COPZ1-depleted naive TPC-1 and
8505C cells. In both cell lines, the endogenous LC3-II was barely
detectable at 48 h and progressively increased at the latest time
points (Fig. 2C). Since an increased steady-state expression of LC3-II
could suggest persistent accumulation of autophagosomes,
impaired recycling and consequently block of the autophagic ﬂux,
we investigated whether COPZ1 depletion causes abortive auto-
phagy. We monitored by WB whether LC3-II accumulation was
associated with increased expression of SQSTM1/p62, an LC3-
binding protein mainly degraded through autophagy catabolism
and whose increase is a marker of abortive autophagy [31]. We
observed an increase of SQSTM1/p62 in both COPZ1-depleted cell
lines in comparison to controls (Fig. 2D). Such increase was 1.4 and
1.6 fold in TPC-1 cells at 72 h and 96 h, and 2.9 and 2.5 fold in 8505C
cells. The persistent accumulation, rather than turnover/degrada-
tion of autophagosomes, and the concomitant increase of SQSTM1/
p62 protein expression suggest that COPZ1 depletion is associated
with abortive autophagy.
COPZ1 depletion induces endoplasmic reticulum stress and unfolded
protein response
As COPZ1 regulates vesicular transport, its depletion could be
associatedwith protein accumulation in the endoplasmic reticulum
(ER) andwith a deﬁcit in proteins coming back from the Golgi. Sincethese effects could be linked to the activation of ER stress and of
unfolded protein response (UPR), we investigated the expression of
some components of these pathways. COPZ1-depleted TPC-1 and
8505C cells showed an increased expression of the chaperone
GRP78/BiP, which, upon ER stress, is the major responsible for the
activation of downstream UPR signals [32,33]. In TPC-1 cells, the
level of GRP78/BiP increases by 1.5, 2.8 and 11 fold at 48 h, 72 h and
96 h after siRNA transfection, respectively, in comparison to the
control; whereas, in 8505C cells the increase was by 1.8, 3.9 and 3.2
fold (Fig. 3A). Concomitantly, we observed an increase of another
marker of ER stress, the ER lumen chaperone calnexin (1.2 at 48 h
and 1.6 from 72 h fold increase in TPC-1; 1.4 and 2.8 fold increase in
8505C cells) (Fig. 3A). CHOP, also known as GADD153, is tran-
scriptionally upregulated during ER stress and UPR [34,35]. We
analyzed the expression of CHOP and COPZ1 by Real Time PCR in
TPC-1 and 8505C cells at different time points after COPZ1
silencing. As shown in Fig. 3B, COPZ1 depletion led to a drastic
increase of CHOP expression in comparison to the control. In
conclusion, our data indicate that COPZ1 depletion causes the onset
of ER stress and UPR.
COPZ1 depletion induces apoptotic cell death
Prolonged ER stress or failure of adaptive response can result in
cell death [36]. Moreover, CHOP activation triggers apoptotic death
[34,35]. TPC-1 and 8505C cells were transfected with siCOPZ1 or
siNT oligos in the presence of the ﬂuorescent substrate for acti-
vated caspase-3/7. Live-cell ﬂuorescence microscopy performed
72 h after transfection showed a signiﬁcant increase of Caspase-3/
7 activity in COPZ1-depleted cells in comparison to the siNT con-
trol (Fig. 4A). The induction of apoptosis by siCOPZ1 is also
documented by the WB analysis in Fig. 4B: COPZ1 depletion in-
creases cleaved PARP and cleaved caspase-3 levels, which were
detectable at 48 h and 72 h after siRNA transfection in TPC-1 and
8505C cells, respectively. Overall, these results suggest that the
depletion of COPZ1 induces caspase-dependent apoptosis in thy-
roid tumor cells.
In vivo effects of COPZ1 depletion
Weused 8505C cell mouse xenografts as in vivomodel of thyroid
carcinogenesis and, in a preliminary experiment, we tested the
in vivo efﬁcacy of siRNA targeting COPZ1. Nude mice were xeno-
grafted with 8505C cells and then locally treated with siCOPZ1,
explanted and analyzed byWB three days later. As shown in Fig. 5A,
a consistent reduction (by 40%) of COPZ1 protein in siCOPZ1-
treated tumor in comparison to vehicle- or siNT-treated control
was observed. The expression of COPZ1 protein in tumor explants
was also analyzed by immunohistochemistry (IHC). The intensity of
staining for COPZ1 in siCOPZ1 explant was reduced in comparison
to siNT explant: score 1þ vs 3þ. This was associated with a
reduction of the rate of proliferating cells, determined by Ki67
staining: 15% in siCOPZ1 explant vs 50% in siNT explant (Fig. 5B).
After proving the efﬁcacy of siCOPZ1 in an in vivo setting, we
evaluated the effect of COPZ1 silencing on in vivo tumor growth.
Nude mice were xenografted with 8505C cells and, at day 17 after,
they were locally treated twice a week with siCOPZ1, or with siNT,
or with the vehicle only. At day 34, tumors were excised and
weighted. As shown in Fig. 5C, treatment with siCOPZ1 signiﬁcantly
reduced tumor growth compared to siNT or vehicle treatments
(controls). Then, tumor explants were analyzed by IHC for the
expression of COPZ1 protein. COPZ1 immunostaining was high in
two siNT samples and ranged from medium to high in two other
samples. Conversely, in COPZ1-depleted explants it was very low
(two samples), low with medium areas (two samples) or medium
Fig. 2. Effect of COPZ1 silencing on autophagy. (A) Percentage of TPC1- and 8505C-GL3 cells displaying LC3 puncta at different time points after siCOPZ1 and siNT oligos trans-
fection; the asterisks indicate differences signiﬁcant by the unpaired Student's t-test (*P < 0.05, **P < 0.01). (B) Representative pictures of TPC1- 8505C-GL3 cells, 48 h and 72 h after
siRNA transfection, respectively; cells were analyzed by ﬂuorescence microscopy for the presence of LC3 puncta (green; arrows); nuclear DNA was stained with DAPI. (C-D) TPC-1
and 8505C cells were analyzed by WB for the expression of LC3-I/II, SQSTM1/p62 and COPZ1 proteins, at the indicated time points after siRNA transfection; b-actin was used for
normalization of gel loading. In 8505C cells (D), p62 and COPZ1 expression in the same cell extracts was assessed in two separate gels.
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(Ki67) was 53.7% for siNT and 31% for siCOPZ1 explants. Concomi-
tantly, when we evaluated the neoplastic cellularity, we observed
an increase of necrosis (20%) in siCOPZ1 explants in comparison
with the controls (11.2%) (Fig. 5D). Representative pictures of
selected explants are shown in Fig. 5E: the siNT-9 sample showedhigh COPZ1 and Ki67 (50%) expression and low necrotic cells (5%),
whereas the siCOPZ1-19 sample displayed an opposite state, being
the COPZ1 staining low, Ki67 20% and necrotic cells 25%. Overall,
our results demonstrated that the local treatment with siCOPZ1
productively reduced tumor growth in our model of thyroid car-
cinoma in nude mice.
Fig. 3. Effect of COPZ1 silencing on ER stress and UPR. (A) WB analysis of calnexin and BiP protein expression in TPC-1 and 8505C cells, at the indicated time points after siRNA
transfection; b-actin was used for normalization of gel loading. In TPC-1 cells, calnexin, COPZ1 and BiP expression in the same cell extracts was assessed in two separate gels; in
8505C cells, calnexin and BiP expression was assessed in the same gel of Fig. 2D. (B) Real-time PCR analysis of COPZ1 and CHOP gene expression in TPC-1 and 8505C cells at the
indicated time points after siRNA transfection; results are presented as log10-transformed relative quantity (RQ) of COPZ1/CHOP mRNA normalized for HPRT1 housekeeping gene
expression. Data represent the mean ± sd of two independent experiments.
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COPZ1 vulnerability is related to downregulation of the paral-
ogous COPZ2 gene in tumor cells. While normal cells tolerate COPZ1
inhibition because COPZ2 can replaces its activity in the COPI
complex, the absence of COPZ2 in tumor cells confers sensitivity to
COPZ1 depletion. Interestingly, COPZ2was found downregulated in
several primary tumors compared to their normal counterparts
[13]. We have previously provided evidence that dependence of
thyroid tumor cell lines on COPZ1 may result from downregulation
of COPZ2, since COPZ2 mRNA expression is downregulated in the
majority of analyzed thyroid tumor cell lines [9]. In order to assess
whether also thyroid tumors belonging to different histotypes may
be sensitive to COPZ1 targeting, we interrogated several publicly
available datasets for the expression status of COPZ2. The ﬁrst
analysis combined data from different datasets, including 58
normal thyroid, 72 PTC, 17 PDTC and 31 ATC samples [20e24]:
COPZ2 was found downregulated in all the tumor histotypes
(Fig. 6A). Furthermore, COPZ2 gene was signiﬁcantly down-
regulated in the 58 PTC samples from the thyroid TCGA dataset
[28], compared to the paired normal counterpart (Fig. 6B, left).
Therefore, the frequent downregulation of COPZ2 in thyroid tumors
allow predicting their sensitivity to COPZ1 inhibition.
The ﬁrst intron of the COPZ2 gene encodes the precursor of miR-
152 [37], which exerts a tumor suppressor role and is frequently
downregulated in several tumors. miR-152 and its hosting gene
COPZ2 are transcribed from the same promoter and are concur-
rently silenced in tumor cells [13]. To assess mirR-152 expression in
thyroid tumors, datawere retrieved from TCGA and correlated withCOPZ2 expression. The analysis shows a notable positive correlation
between COPZ2 and hsa-miR-152 RNAseq expression levels (Fig. 6B,
right). This result indicates that miR-152, concurrently to COPZ2, is
downregulated in thyroid cancer and it may exert an oncosup-
pressor role also in this tumor type.
Discussion
By performing a siRNA-based functional screening, we have
recently discovered several thyroid tumor cell vulnerabilities,
consisting in a set of genes, deﬁned non-oncogenes, whose
silencing inhibited the growth of a panel of thyroid tumor cells, but
not that of normal immortalized thyrocytes. The COPZ1 gene was
found among the top signiﬁcant genes, exerting a role in sustaining
the phenotype of thyroid tumor cells. In this study, we dissected the
mechanisms leading to cell lethality upon COPZ1 depletion and
explored its employability as therapeutic target for thyroid
carcinoma.
First, we conﬁrmed that COPZ1 represents vulnerability for
several thyroid tumor cell lines since its silencing drastically im-
pairs their viability and demonstrated the lack of effect also in
normal primary thyrocytes and mammary epithelial cells.
Our study, aimed at better characterizing the mechanisms
leading to cell death upon COPZ1 depletion, showed that, similarly
to other members of the coatomer complex [11,30], COPZ1 was a
critical player of autophagy. Indeed, COPZ1 silencing initiated
autophagy, which became abortive due to an increase rather than a
turnover of autophagosomes. Concomitantly, COPZ1-depleted cells
displayed the activation of markers of ER stress and UPR. Whether
Fig. 4. Effect of COPZ1 silencing on cell death. (A) TPC-1 and 8505C cells were transfected with siCOPZ1 or siNT oligos in the presence of 2 mM of the ﬂuorogenic substrate for
activated caspase-3/7; live-cell ﬂuorescence images (10magniﬁcation) were taken 72 h later with microscope. (B) WB analysis of cleaved PARP (arrowhead), cleaved caspase 3 and
COPZ1 protein expression, at the indicated time points after siRNA transfection; b-actin was used for normalization of gel loading. Cleaved PARP expression in the same cell extracts
was assessed in two separate gels.
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stress remains to be investigated. We then demonstrated that the
onset of a prolonged ER stress exacerbates cell death, since COPZ1-
depleted cells rapidly underwent caspase-dependent apoptosis.
Interestingly, in support to what observed by functional studies,
a preliminary gene expression proﬁling of COPZ1-depleted 8505C
cells indicated that the main upregulated canonical pathways
consist of the unfolded protein and ER stress response, lipid
metabolism and cell death (apoptosis). In parallel, proteomic
proﬁling of COPZ1-depleted 8505C cells by nano-scale liquid
chromatographic tandem mass spectrometry, indicated that the
main involved pathways deal with vesicle trafﬁcking, autophagy
and caspase cascade in apoptosis (our unpublished results), in
keeping with what observed by gene expression analysis.
Our results suggest that thyroid tumor cells dependence upon
the activity of COPZ1 may be related to its pivotal involvement onthe regulation of autophagy, UPR and ER stress, processes generally
known as cytoprotective and adaptive mechanisms for cancer cell
survival. Thus, COPZ1 inhibition may represent a strategy to target
these processes and convert their effect into a lethal mechanism.
Interestingly, normal cells, which are probably not strictly depen-
dent on thesemechanisms, are preserved from cell death. However,
apart from the well known role of COPZ1 in vesicle trafﬁcking, the
possible direct involvement of COPZ1 in cancer cell survival is still
unclear. How COPZ1 depletion modulates the activation of intra-
cellular multiple signalling pathways, executors of the ﬁnal lethal
effect, remains to be better investigated. This will allow identifying
other critical nodes in the oncogenic network whose inhibitionwill
result in cell collapse.
In our study, the most striking effect of COPZ1 silencing was
observed in mouse tumor 8505C xenografts: in fact, siCOPZ1-
treated tumors showed a consistent reduction of tumor growth.
Fig. 5. Effect of COPZ1 silencing on 8505C in vivo tumor growth. (A) WB analysis of COPZ1 expression in tumor xenografts, excised three days after siRNA treatment; actin was used
as loading control for cell extracts. The graph represents the densitometric analysis of the bands; data are reported as ratio of COPZ1 to actin and normalized for the siNT sample
value. (B) IHC analysis of COPZ1 and Ki67 expression in siNT and siCOPZ1 tumor explants. (C) In vivo tumorigenicity assay: the line within each box represents the median tumor
weight (g) value of 10 controls (ﬁve vehicle and ﬁve siNT) and six siCOPZ1 treated explants at the end of the experiment (34 days); upper and lower edges of each box represent the
75th and 25th percentile, respectively; upper and lower bars indicate the highest and lowest values less than one interquartile range from the extremes of the box. *P ¼ 0.026,
controls vs. siCOPZ1-treated mice, Kruskal-Wallis Test. (D) Mean percentage of Ki67 positive and necrotic cells in tumor explants (four siNT and ﬁve siCOPZ1 samples); the asterisk
indicates differences signiﬁcant by the unpaired Student's t-test (*P < 0.05). (E) IHC analysis of COPZ1 and Ki67 expression and H&E staining of two representative tumor explants
(siNT-9, siCOPZ1-19); black arrow indicates areas of necrosis.
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Fig. 6. Expression of COPZ2 and mir-152 in thyroid carcinomas. (A) Scatter plot distribution of COPZ2 gene expression levels (log2 scale) in 58 normal thyroid-tissues, 72 PTC, 17
PDTC and 31 ATC primary tumor samples; in the graph the median is recorded. Nonparametric pairwise multiple comparisons between all analyzed groups were performed by
Dunn's test and Benjamini-Hochberg correction, following a signiﬁcant Kruskal-Wallis test (p ¼ 5.733 e11). (B) (left) Scatter plot distribution of RNAseq normalized expression
values (natural scale) from the thyroid TCGA dataset of COPZ2 in 58 matched normal (N) and PTC samples. Illumina HiSeq Level 3 data were downloaded from TCGA Data Portal
website and RSEM gene normalized expression values were derived for 58 PTC patients, in tumor and adjacent normal samples, respectively; in the graph the median is recorded.
Differential gene expression levels between tumor and normal groups were evaluated by Wilcoxon test (p-value ¼ 2.442  1010); (right) dispersion plot of COPZ2 (x-axis) and hsa-
miR-152 (y-axis) RNAseq normalized expression levels (log2 scale) in the 58 PTC samples. Normalized reads per million miRNA mapped (RPM) data were obtained for the same 58
tumor samples from Illumina HiSeq Level 3 isoform quantiﬁcation ﬁles (TCGA Data Portal website), by summing up the reads aligned to each 3p or 5p miRBase v16 mature strands.
Pearson's correlation method was applied to evaluate the correlation between RNAseq normalized gene and miRNA read counts in 58 tumor samples (r ¼ 0.67,
p-value ¼ 8.41  109).
M.C. Anania et al. / Cancer Letters 410 (2017) 201e211 209Moreover, IHC analysis of tumor explants showed that COPZ1
silencing was associated with the decrease of the proliferative
marker Ki67 and with an increase of necrosis. Further studies are
needed to identify the mediators mainly involved in this process.
An attractive hypothesis is that COPZ1 depletion could establish an
inﬂammatory microenvironment through the release of cytokines/
chemokines; this is supported by gene expression proﬁle of COPZ1-
depleted cells, showing upregulation of genes coding for cytokines
involved in mediating communication between immune cells.
More information on mediators released after cell death will be
provided by the characterization of the cellular secretome content
after COPZ1 depletion.
Tumor cell sensitivity to COPZ1 depletion is related to down-
regulation of its paralogous COPZ2 gene. COPZ1 inhibition is
tolerated by normal cells because COPZ2 substitutes for it in the
COPI complex, whereas tumor cells, characterized by the absence of
COPZ2, display sensitivity. This “synthetic lethality” renders COPZ1
depletion an attractive strategy to kill tumor cells. By interrogating
publicly available data sets including a large collection of thyroid
tumors we found that COPZ2was frequently downregulated in PTC,
PDTC and ATC samples, thus indicating that the majority of thyroid
tumors may be eligible for COPZ1 targeting. As reported in other
tumor types [13], we observed a concomitant low expression of
miR-152, encoded within the COPZ2 gene, which exerts a tumor
suppressor role and is donwnregulated in different tumors,
including thyroid ones [38]. Whether the downregulation of COPZ2and miR-152 in thyroid tumors is due to promoter hyper-
methylation, as reported for other tumor types [39], remains to be
investigated. Moreover, we cannot exclude that COPZ1 dependency
of thyroid tumors may also rely on other mechanisms or on other
components of the COPI complex. Indeed, we had previously
observed that the FTC-derived WRO82-1 cell line is sensitive to
COPZ1 depletion, even though it expresses high level of COPZ2
mRNA [9].
Recent reports indicate that, as for COPZ1, targeting other COPI
complex members may represent a therapeutic approach for can-
cer. A siRNA-based functional screening proposed COPA gene,
encoding the a subunit of COPI complex, as a potential therapeutic
target for mesothelioma [40]. Claerhout et al. have shown that
targeting the COPI complex members is a potent approach to block
productive autophagy and stimulate cell death in cancer cells [30].
Recently, ARCN1, the d-subunit of the COPI complex, has been
proposed as a new therapeutic target [41]. COPB2 was found as
synthetic lethal partner of mutated KRAS [42]. The co-occurrence of
mutations in KRAS and LKB1, present in a small fraction of lung
adenocarcinomas, drives addiction to the COPI complex members
[43]. Of note, COPE gene, encoding the ε subunit of COPI complex,
emerged from our screening in the list of genes speciﬁcally inhib-
iting thyroid tumor cell growth [9]. All this evidence suggests that
targeting the coatomer complex, and consequently causing abor-
tive autophagy and ER stress, may represent an optimal strategy to
kill cancer cells, especially those resistant to conventional therapy.
M.C. Anania et al. / Cancer Letters 410 (2017) 201e211210In conclusion, we demonstrated that COPZ1 represents vulner-
ability for thyroid tumor cells, thus providing the ﬁrst evidence of
non-oncogene addiction for this tumor type. This adds a new
element to the list of potential therapeutic targets, which includes,
in addition to the driver oncogenic proteins and downstream
pathways, several genes and miRNAs differentially expressed in
thyroid tumors, some of which identiﬁed by our group
[17,18,44e47], and whose role in promoting or suppressing the
transformation process has been functionally demonstrated. On the
whole, our results pave the way for designing novel therapeutic
approaches based on COPZ1 inhibition useful for thyroid tumor
patients who do not respond to standard therapies and rapidly
progress to malignant forms. Notably, being effective on tumor but
not on normal cells, these novel therapeutic approaches may have
limited side effects.
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